CDKN2A and breast cancer: GSTP1 and MGMT in combination with CDKN2A and ARF have diagnostic power in the urine of patients with BC [239], and GSTP1 together with TIMP3 promoter methylation allowed the discrimination of invasive tumors [13,239].